How do I quickly develop first-in-human (FIH) dosage forms and avoid CMC delays whilst achieving proof-of-concept (POC)?
Overview
Download Quotient Sciences', 'How do I quickly develop first-in-human (FIH) dosage forms and avoid CMC delays whilst achieving proof-of-concept (POC)?'.
Our scientific poster includes the following:
- Choosing the appropriate dosage form for first-in-human clinical trials
- Deciding between a pharmacy preparation or GMP manufacturing
- Bridging to robust and scalable Phase II drug products
- Flexible and adaptive clinical manufacturing strategies for patient trials
- Integrating pharmaceutical sciences and clinical testing